Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2018-06-05 Declaration of Voting R…
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filing dated June 4, 2018, reporting the submission of matters to a vote of security holders at the company's 2018 Annual Meeting of Shareholders. It details the voting results for election of directors, appointment of the independent registered public accounting firm, and authorization of audit committee remuneration. The content focuses on official results from shareholder votes at a general meeting. The document length is 4394 characters, which is relatively short but contains detailed voting results, not just an announcement of a report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-06-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions the announcement of two press releases regarding clinical updates and preclinical data for product candidates. There are no financial statements or detailed financial data included, only references to press releases attached as exhibits. The document length is 3017 characters, which is relatively short and consistent with an announcement rather than a full report. The content does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is primarily a regulatory filing announcing other events and attaching press releases. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-05-15 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to an at-the-market equity offering of common shares. It includes detailed information about the offering, use of proceeds, risk factors, plan of distribution, and legal matters. The document is a formal disclosure related to capital raising activities, specifically an equity offering. It is not an annual or quarterly report, earnings release, or management discussion. It is not a proxy statement, voting results, or governance information. The document fits the definition of a Capital/Financing Update as it provides updates on company fundraising and capital structure changes through an equity offering.
2018-05-08 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2018, reporting the entry into a material definitive agreement for an at-the-market equity offering sales agreement. The content focuses on the details of the sales agreement, the parties involved, and related legal opinions. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The document is an announcement of a capital raising activity and related agreement, which fits the category of Capital/Financing Update filings. The document length is 6860 characters, which is consistent with a detailed 8-K filing but not a full financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-05-08 English
10-Q
Interim / Quarterly Report Q1 2018
2018-05-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically states that the company announced its financial results for the quarter ended March 31, 2018, via a press release attached as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length is 3175 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing financial results via press release in a Form 8-K is classified as an Earnings Release (ER).
2018-05-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.